Scinai Immunotherapeutics
SCNI
2 hedge funds and large institutions have $126K invested in Scinai Immunotherapeutics in 2015 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 2 closing their positions.
0.09% less ownership
Funds ownership: 0.26% → 0.17% (-0.09%)
29% less capital invested
Capital invested by funds: $177K → $126K (-$51K)
50% less funds holding
Funds holding: 4 → 2 (-2)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$46K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$13K |
| 3 |
Citigroup
New York
|
-$1K |
SCNI Hedge Fund Activity: Q4 2015 in Review
2 of the 3,824 institutional investors tracked by Wall St. Rank reported a position in Scinai Immunotherapeutics (SCNI) for Q4 2015, worth a combined $126K — down 29% from $177K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of SCNI and 0 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Jane Street, exiting entirely with an estimated $46K sold.
- 2 institutional investors held Scinai Immunotherapeutics (SCNI) as of Q4 2015, down from 4 in Q3 2015.
- Funds reported $126K of Scinai Immunotherapeutics stock for Q4 2015, down 29% quarter-over-quarter.
- 0 funds opened new Scinai Immunotherapeutics positions in Q4 2015 and 2 closed out, a net change of -2 holders.
- The largest Scinai Immunotherapeutics seller in Q4 2015 was Jane Street, an estimated $46K sold.
Based on aggregated 13F filings for Q4 2015.